Business context and reporting period
Apollomics Inc. is a Cayman Islands clinical-stage biotechnology company developing oncology therapies. Its pipeline includes nine product candidates across 11 programs, with vebreltinib (APL-101) and uproleselan (APL-106) as leading candidates. The filing is a Form 20-F for the fiscal year ended December 31, 2023, not a standalone fourth-quarter filing. The company completed its business combination with Maxpro Capital Acquisition Corp. on March 29, 2023 and began trading on Nasdaq on March 30, 2023.
Financial performance and position
| Metric | 2023 | 2022 | Change |
|---|---|---|---|
| Revenue | $0 | $0 | No product revenue |
| Net loss | $172.6 million | $240.8 million | Loss decreased $68.2 million |
| Loss from operations excluding preferred-share fair value changes and listing-related effects | $50.7 million | $51.2 million | Broadly stable |
| Research and development expense | $34.2 million | $35.5 million | Decreased 3.6% |
| Administrative expense | $20.6 million | $9.9 million | Increased 107.5% |
| Net cash used in operating activities | $43.2 million | $42.8 million | Broadly stable |
| Cash and cash equivalents | $32.1 million | $32.7 million | Decreased $0.6 million |
| Cash, cash equivalents and financial assets at FVTPL | $37.8 million | $58.9 million | Decreased $21.1 million |
| Short-term bank loans | $4.2 million | $0 | New borrowing |
| Net assets | $41.2 million | Net liabilities of $448.1 million | Improved following business combination and conversion of preferred shares |
Operating margins and profitability ratios are not meaningful because the company has no product revenue and remains loss-making. Basic and diluted loss per share was $2.32 in 2023 versus $8.44 in 2022, reflecting the post-business-combination capital structure and higher weighted-average share count.
Material changes versus the prior comparable period
- Research and development spending declined modestly as the company prioritized key programs, while employee share-based compensation increased by $3.5 million.
- Administrative expense increased primarily due to $6.2 million of additional share-based compensation, $3.9 million of business-combination-related third-party fees and $2.4 million of other transaction-related expenses.
- The company recorded a $45.5 million IFRS 2 listing expense associated with the Maxpro transaction. This was a non-cash charge and materially affected reported net loss.
- The fair value loss on convertible preferred shares fell to $76.4 million from $189.6 million. All pre-closing preferred shares converted into ordinary shares on March 29, 2023, eliminating the preferred-share liability at year-end.
- Financing cash flow was positive $21.2 million, including $20.2 million of net PIPE financing and business-combination proceeds and $4.2 million of bank-loan proceeds, partly offset by deferred underwriting fees and lease payments.
- Vebreltinib was conditionally approved and launched in China by partner Avistone in November 2023 for locally advanced or metastatic NSCLC with MET exon 14 skipping mutations. The filing does not report product revenue to Apollomics from this approval.
Guidance, outlook, commentary and risks
Management implemented significant expense reductions in January 2024 and prioritized vebreltinib and uproleselan. The filing contains inconsistent liquidity language: one disclosure estimates sufficient liquidity through at least December 31, 2024, while another estimates liquidity through the first quarter of 2025. In either case, management states that additional equity, debt or strategic-partnership capital will be required to continue as a going concern thereafter.
- Vebreltinib global development is focused on NSCLC with MET exon 14 skipping, NSCLC with MET amplification and glioblastoma with MET alterations. Management discussed a potential U.S. NDA for MET-amplified NSCLC in 2026 if additional data are positive; this is an expectation, not firm guidance.
- In combined SPARTA and KUNPENG data for treatment-naive NSCLC with MET exon 14 skipping, the reported ORR was 66.2% and median duration of response was 16.5 months. These analyses are preliminary or interim and remain subject to regulatory review and further follow-up.
- Uproleselan’s China Phase 3 bridging study in relapsed or refractory AML completed enrollment of 140 patients in December 2023. GlycoMimetics’ global Phase 3 study was expected to report topline results in the second quarter of 2024.
- Vebreltinib safety data included treatment-related grade 3 or higher adverse events in 42.2% of patients in the cited SPARTA-II and KUNPENG data, with edema and ALT increases among the most common. The company has also observed elevated liver enzymes in clinical trials.
- Key risks include clinical-trial failure or delay, regulatory non-approval, reliance on CROs, CMOs and licensing partners, additional financing and dilution, pricing and reimbursement uncertainty, China-related data and currency controls, cybersecurity and data-protection compliance, intellectual-property disputes, and competition from approved c-Met therapies.
- The company identified one material weakness and three significant deficiencies in internal control over financial reporting as of December 31, 2023. Remediation was in progress and had not been completed by the filing date.
- Nasdaq notified the company in January 2024 that its share price had remained below the $1.00 minimum bid-price requirement for 30 consecutive business days. The company had until July 15, 2024, subject to potential extension, to regain compliance.
- Third-party intellectual-property patents potentially relevant to vebreltinib are expected to expire in December 2026, creating possible licensing, litigation or commercialization-delay risks.
Most important facts for investors to verify
- Reconcile the filing’s conflicting liquidity estimates of December 31, 2024 versus the first quarter of 2025.
- Confirm current cash, cash equivalents, restricted cash, money-market investments, bank-loan balances and borrowing maturities after December 31, 2023.
- Track financing activity, potential dilution, outstanding options and approximately 11.0 million public, private and extension warrants, plus penny warrants.
- Verify the regulatory status, confirmatory-trial requirements and commercialization economics for vebreltinib in China and potential U.S. indications.
- Review final, centrally confirmed clinical data rather than relying solely on preliminary ORR and duration-of-response results.
- Assess the outcome of the global uproleselan Phase 3 study and Apollomics’ China bridging study.
- Monitor remediation of the material weakness and significant deficiencies and any future restatement or control-related disclosure.
- Monitor Nasdaq bid-price compliance and the potential need for a reverse stock split.
- Review licensing obligations, milestone payments, royalties and the potential impact of third-party patents on vebreltinib commercialization.